Immunogenicity and safety of three consecutive lots of a new preservative-free inactivated hepatitis A vaccine (Healive®): A double-blind, randomized and controlled trial

Vaccine

Volumn 26, Issue 18, 2008, Pages 2297-2301

  Jiang, Wei Ping ^a   Chen, Jiang Ting ^b   Wang, Xu ^b   Wang, Ya Long ^a   Liu, Yan ^b   Chen, Wen Yu ^a   Xu, Wen Guo ^a   Qiu, Yuan Zheng ^b   Yin, Wei Dong ^b  

^a Changzhou Center for Disease Control and Prevention   (China)

^b Sinovac Biotech Co Ltd   (China)

Author keywords

Consistency; Hepatitis A inactivated vaccine; Immunogenicity; Safety

Indexed keywords

HEALIVE; HEPATITIS A VACCINE; INACTIVATED VACCINE; UNCLASSIFIED DRUG;

ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSAGE FORM COMPARISON; DRUG DOSE REGIMEN; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GEOMETRY; HEPATITIS A; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE REACTION; MALE; MULTIPLE CYCLE TREATMENT; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; STATISTICAL ANALYSIS; UNSPECIFIED SIDE EFFECT; VACCINATION; VIRUS TITRATION; VOMITING;

CHILD; CHILD, PRESCHOOL; DOUBLE-BLIND METHOD; FEMALE; HEPATITIS A; HEPATITIS A ANTIBODIES; HEPATITIS A VACCINES; HUMANS; IMMUNIZATION, SECONDARY; INFANT; MALE; VACCINES, INACTIVATED;

EID: 42249105031     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.11.008     Document Type: Article

References (17)

1. Anonymous. Hepatitis A vaccines. WHO position paper. Wkly Epidemiol Rec 2000; 75: 38-44.
2. Poovorawan Y., Paiboonkasemsuthi S., Theamboonlers A., Kamolratanakul P., and Chumdermpadetsuk S. Seroepidemiology of antibody to hepatitis A in the rural eastern part of Thailand. Southeast Asian J Trop Med Public Health 22 (1991) 35-38
3. Gust I.D. Epidemiological patterns of hepatitis A in different parts of the world. Vaccine 10 (1992) 56-58
4. Koff R.S. Hepatitis A. Lancet 351 (1998) 1643-1649
5. Willner I.R., Uhl M.D., Howard S.C., Williams E.Q., Ricly C.A., and Waters B. Serious hepatitis A: an analysis of patients hospitalized during an urban epidemic in the United States. Ann Int Med 128 (1998) 111-114
6. André F.E., D'Hondt E., Delem A., and Safary A. Clinical assessment of the safety and efficacy of an inactivated hepatitis A vaccine: rationale and summary of findings. Vaccine 10 Suppl. 1 (1992) S160-S168
7. André F.E., Hepburn A., and D'Hondt E. Inactivated candidate vaccines for hepatitis A. Prog Med Virol 37 (1990) 72-79
8. Theilmann L., Kallinowski B., Gmelin K., Hofmann F., Scheiermann N., Wohland B., et al. Reactogenicity and immunogenicity of three different lots of a hepatitis A vaccine. Vaccine 10 Suppl. 1 (1992) S132-S134
9. Werzberger A., Mensch B., Kuter B., Brown L., Lewis J., Sitrin R., et al. A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children. N Engl J Med 327 (1992) 453-457
10. Innis B.L., Snitbhan R., Kunasol P., Laorakpongse T., Poopatanakool W., Kozik C.A., et al. Protection against hepatitis A by an inactivated vaccine. JAMA 271 (1994) 1328-1334
11. Clemens R., Safary A., Hepburn A., Roche C., Stanbury W.J., and André F.E. Clinical experience with an inactivated hepatitis A vaccine. J Infect Dis 171 Suppl. 1 (1995) S44-S49
12. Barzaga N.G. Hepatitis A shifting epidemiology in South-East Asia and China. Vaccine 18 (2000) S61-S64
13. Freed G.L., Andreae M.C., Cowan A.E., and Katz S.L. The process of public policy formulation: the case of thimerosal in vaccines. Pediatrics 109 (2002) 1153-1159
14. Centers for Disease Control and Prevention. Notice to readers: thimerosal in vaccines: a joint statement of the American Academy of Pediatrics and the Public Health Service. MMWR Morb Mortal Wkly Rep 1999; 48:563-5.
15. Ren A.G., Feng F.M., Ma J.R., Xu Y.J., and Liu C.B. Immunogenicity and safety of a new inactivated hepatitis A vaccine in young adults: a comparative study. Chin Med J 115 (2002) 1483-1485
16. Ren Y.H., Chen J.T., Wu W.T., Gong X.J., Zhang Y.C., Xue W.H., et al. The study on the 0, 12 month vaccination schedule of Healive (inactivated hepatitis A vaccine in children. Chin J Epidemiol 24 (2003) 1013-1015
17. ® inactivated hepatitis A vaccine in young children. Chin. Prev Med 5 (2004) 102-103